Abstract
Objectives Insomnia often leads to systemic chronic inflammation and is particularly common among asthma patients. However, the specific impact of insomnia on lung function and mortality in asthma patients remains unclear. This study aims to investigate the relationship between insomnia, lung function, and mortality in asthma patients, and further elucidate the potential role of inflammatory biomarkers in this association. Study design This was a prospective cohort study. Methods This prospective cohort study using data from the UK Biobank included 37250 participants with asthma. Multiple linear regression and Cox proportional hazards models were separately used to explore the relationships between insomnia, lung function, and mortality. Mediation analysis assessed the mediating effects of inflammatory biomarkers. Results Compared to those without insomnia, frequent insomnia was associated with a 0.06 decline in FEV1 (Z-score) and a 0.11 reduction in FEV1/FVC (Z-score). The Hazard ratios (HRs) for individuals with frequent insomnia were 1.10 (95 % CI: 1.01-1.19) for all-cause mortality and 1.15 (95 % CI: 1.02-1.29) for cancer-related mortality. Inflammatory biomarkers mediated the association between insomnia and mortality, proportions(%) were WBC (5.86), NEU (11.9), SII (5.71), LCR (15.3) and CRP (13.8). Conclusion Insomnia in asthma patients is negatively associated with lung function and increases the risks of both all-cause and cancer-related mortality. Inflammatory biomarkers partially mediate this association.</p>